Changes in Beneficial Ownership · 4
Legend Biotech Corp
Changes in Beneficial Ownership
Structured filing — 4
form4-10012026_081003.xml
Filing details
- Report period
- 2026-09-29
- Issuer
- Legend Biotech Corp
- Issuer CIK
- 0001801198
- Trading symbol
- LEGN
Reporting owner 1
- Name
- Sanders Corazon (Corsee) D.
- Reporting owner CIK
- 0001796536
- Relationship
- Director
- Address
- C/O LEGEND BIOTECH CORP, 77 CORPORATE DRIVE, 4TH FLOOR, BRIDGEWATER, NJ, 08807
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Ordinary Shares[F1] | 2026-09-29 | S · Form 4 | 27,370 | D | 9.46[F2] | 52,731 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.↩ 1
- F2
- The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.445 to $9.48 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
Signature 1
- Signed
- /s/ Robert Staloff, Attorney-in-Fact
- Date
- 2026-10-01
Company context
With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.